Use of Beta-lapachone for Lung Cancer Chemotherapy

β-拉帕酮在肺癌化疗中的用途

基本信息

  • 批准号:
    7938142
  • 负责人:
  • 金额:
    $ 17.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2011-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) patients have a dismal five year survival rate of ~15%. Antitumor agents that target unique protein markers to kill NSCLC cells irrespective of growth state, and target primary and metastatic cells, are desperately needed. We completed all the proposed Aims in the prior granting period and elucidated the mechanism of action of ¿-lapachone (¿-lap) alone against NSCLC cells. ¿-Lap was selectively efficacious for NSCLCs, in which >80% tumors had 5- to >100-fold endogenous overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1). ¿-Lap kills NSCLC cells through an NQO1/ROS/Ca2+ER/PARP1 hyperactivation pathway, leading to ¿-calpain cell death. To overcome solubility and normal tissue toxicity problems, various ¿-lap delivery methods were developed. Arq501 (¿-lap in hydroxypropyl-¿-cyclodextrin, Arqule Chem. Co., MA) entered several Phase II clinical trials based on our work. Several novel nanoparticle micelle delivery systems that will increased the efficacy of ¿-lap or pH-sensitive ¿-lap prodrugs alone, or in combination with radiation therapy, will be explored in this competitive renewal. We hypothesize that cancer-targeted, pH-sensitive nanoparticle micelles loaded with ¿-lap or ¿-lap pH-sensitive prodrugs can be used to significantly increase the efficacy of ¿-lap alone, and in combination with ionizing radiation (IR) therapy (XRT). IR + ¿-lap synergy results from meeting a accumulative damage threshold, that in turn stimulates the NQO1/ROS/ Ca2+ER/PARP1 hyperactivation pathway that activates ¿-calpain, a programmed necrotic/apoptotic pathway unique to ¿-lap cell killing. Three Aims will be completed: Aim 1. To elucidate the mechanism of action of ¿-lap as a radiosensitizer. (Years 1-5). Aim 2: To design and develop stealth, cancer-targeting nanoparticle micelles loaded with ¿-lap or pH- sensitive ¿-lap prodrugs to efficaciously treat human NSCLCs. (Years 1-5). Aim 3: To elucidate and optimize the pharmacokinetics and antitumor activity in vivo of ¿-lap-loaded nanoparticle micelles alone and with XRT against NSCLCs as xenograft or orthotopic models (Years 1-5). The ultimate goal of this grant is to develop a platform of ¿-lap compounds delivered by nanoparticle micelles that can efficacious treat NSCLC by exploiting their unique overexpression of NQO1. PUBLIC HEALTH RELEVANCE: Patients with nonsmall cell lung cancer (NSCLC) have little hope of being cured of their diseases, with five-year survival rates at only 15%. This competitive renewal will build on the many findings of the prior grant, including: (i) evaluation and demonstration of elevated (5- to 100-fold) NQO1 levels in NSCLC populations from Hong Kong and New York; (ii) elucidation of ¿-lap mechanism of action; (iii) development of novel ¿-lap-encoded nanoparticles; (iv) development of pH sensitive ¿-lap prodrugs; (v) efficacious antitumor activity of ¿-lap against orthotopic, as well as xenograft models of A549 NSCLCs; and (vi) development of functionalized nanoparticles that can target the angiogenic endothelial cells that innervate the tumor neovasculature. The ultimate goal of these studies is to develop a nanoparticle platform for the cancer-targeted delivery of ¿-lap and its pH-sensitive prodrugs for the eradication of nonsmall cell lung cancers.
描述(由申请人提供):非小细胞肺癌(NSCLC)患者的五年生存率很低,约为15%。迫切需要靶向独特的蛋白质标记物以杀死NSCLC细胞(无论生长状态如何)并靶向原发性和转移性细胞的抗肿瘤药物。我们在之前的授权期内完成了所有拟定的目的,并阐明了单用拉帕酮(<$-lap)对NSCLC细胞的作用机制。<$-Lap对NSCLC选择性有效,其中> 80%的肿瘤具有5至> 100倍的NAD(P)H:醌氧化还原酶1(NQO1)内源性过表达。<$-Lap通过NQO1/ROS/Ca2 + ER/PARP1超活化途径杀死NSCLC细胞,导致<$-calpain细胞死亡。为了克服溶解度和正常组织毒性问题,开发了各种² lap输送方法。Arq501(羟丙基-β-环糊精中的β-lap,Arqule Chem.Co.,MA)基于我们的工作进入了多个II期临床试验。几种新的纳米粒子胶束递送系统,将增加单独或与放射治疗相结合的<$-lap或pH敏感性<$-lap前药的疗效,将在这种竞争性更新中进行探索。我们假设,装载有<$-lap或<$-lap pH敏感性前药的癌症靶向pH敏感性纳米颗粒胶束可用于显著增加<$-lap单独使用以及与电离辐射(IR)治疗(XRT)联合使用的疗效。IR+?- lap协同作用是由于达到累积损伤阈值,这反过来又刺激NQO1/ROS/Ca2 + ER/PARP1超活化途径,从而激活<$-钙蛋白酶,这是<$-lap细胞杀伤所特有的程序性坏死/凋亡途径。将完成三个目标:目标1。阐明?-lap作为放射增敏剂的作用机制。(1 - 5年级)。目标二:设计和开发负载有<$-lap或pH敏感性<$-lap前药的隐形、癌症靶向纳米粒子胶束,以有效治疗人NSCLC。(1 - 5年级)。目标三:阐明并优化单用和与XRT联合使用的负载有lap的纳米颗粒胶束对NSCLC作为异种移植物或原位模型的体内药代动力学和抗肿瘤活性(第1 - 5年)。这项资助的最终目标是开发一种由纳米粒子胶束递送的纳米-lap化合物平台,通过利用其独特的NQO1过表达来有效治疗NSCLC。公共卫生关系:非小细胞肺癌(NSCLC)患者治愈的希望很小,五年生存率仅为15%。这次竞争性更新将建立在先前赠款的许多发现的基础上,包括:(i)评估和展示提升的(5 - 100倍)NQO1水平;(ii)阐明<$-lap的作用机制;(iii)开发新型<$-lap编码的纳米颗粒;(iv)开发pH敏感性<$-lap前药;(v)?-lap对A549 NSCLC的原位以及异种移植模型的有效抗肿瘤活性;以及(vi)开发能够靶向支配肿瘤新血管系统的血管生成内皮细胞的功能化纳米颗粒。这些研究的最终目标是开发一种纳米颗粒平台,用于靶向递送<$-lap及其pH敏感性前药,以根除非小细胞肺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David A Boothman其他文献

Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation
在临床相关剂量电离辐射后哺乳动物细胞中激活的转录因子
  • DOI:
    10.1038/sj.onc.1206680
  • 发表时间:
    2003-08-28
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Tracy Criswell;Konstantin Leskov;Shigeki Miyamoto;Guangbin Luo;David A Boothman
  • 通讯作者:
    David A Boothman
A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage
DNA 错配修复在感知和响应氟嘧啶损伤中的作用
  • DOI:
    10.1038/sj.onc.1206941
  • 发表时间:
    2003-10-23
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Mark Meyers;Arlene Hwang;Mark W Wagner;Andrew J Bruening;Martina L Veigl;W David Sedwick;David A Boothman
  • 通讯作者:
    David A Boothman

David A Boothman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David A Boothman', 18)}}的其他基金

Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
PARP 抑制剂针对 NQO1 非小细胞肺癌的肿瘤选择性使用
  • 批准号:
    9401993
  • 财政年份:
    2017
  • 资助金额:
    $ 17.58万
  • 项目类别:
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
PARP 抑制剂针对 NQO1 非小细胞肺癌的肿瘤选择性使用
  • 批准号:
    9502256
  • 财政年份:
    2017
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8100383
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8726518
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8657848
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8017553
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8458576
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8824333
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 结合蛋白-5 (KUB5),非同源末端连接的新因子
  • 批准号:
    8257942
  • 财政年份:
    2010
  • 资助金额:
    $ 17.58万
  • 项目类别:
Use of Beta-lapachone for Lung Cancer Chemotherapy
β-拉帕酮在肺癌化疗中的用途
  • 批准号:
    8689943
  • 财政年份:
    2003
  • 资助金额:
    $ 17.58万
  • 项目类别:

相似海外基金

Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
  • 批准号:
    10607815
  • 财政年份:
    2023
  • 资助金额:
    $ 17.58万
  • 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
  • 批准号:
    10723868
  • 财政年份:
    2023
  • 资助金额:
    $ 17.58万
  • 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
  • 批准号:
    10862033
  • 财政年份:
    2023
  • 资助金额:
    $ 17.58万
  • 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
  • 批准号:
    10622209
  • 财政年份:
    2023
  • 资助金额:
    $ 17.58万
  • 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
  • 批准号:
    22H03963
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
  • 批准号:
    10356565
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10708827
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
  • 批准号:
    10388929
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
Role of natural immunity to self apoptotic exosomes in maintaining immune homeostasis
对自凋亡外泌体的自然免疫在维持免疫稳态中的作用
  • 批准号:
    RGPIN-2021-03004
  • 财政年份:
    2022
  • 资助金额:
    $ 17.58万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了